Breaking News

Crucell, DSM Sign License Agreement with MorphoSys

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Crucell and technology partner DSM Biologics have signed a second PER.C6 license agreement with MorphoSys AG. This license agreement allows MorphoSys to use the PER.C6 cell line in the production of clinical grade material for the development of its proprietary therapeutic antibody program MOR103. MOR103 is a fully human HuCAL antibody, developed in the area of inflammatory diseases, such as rheumatoid arthritis. Also, MorphoSys has signed a biopharmaceutical manufacturing agreement with...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters